Health Care • Biotechnology: Pharmaceutical Preparations
$50.39 ▼ -0.18
(-0.36%)
MKT CAP: $4.75B • VOL: 1.14M
52W L $23 52W H $69
TVTX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $490.7M | $233.2M | $145.2M |
| YoY Revenue Growth % | +110.5% | +60.5% | — |
| Gross Profit | $480.4M | $225.4M | — |
| Gross Margin % | 97.9% | 96.7% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$62.8M | -$323.8M | -$388.1M |
| Operating Margin % | -12.8% | -138.9% | -267.2% |
| Net Income (GAAP) | -$25.5M | -$321.5M | -$111.4M |
| EBITDA (Normalized) | -$45.2M | -$315.4M | -$382.9M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $37.8M | -$237.5M | -$280.0M |
| Capital Expenditures (CapEx) | $22.1M | $10.5M | $6.5M |
| Free Cash Flow (FCF) | $15.7M | -$248.0M | -$286.6M |
| FCF Margin % | 3.2% | -106.3% | -197.3% |
| Return on Invested Capital (ROIC %) | -20.5% | -45.0% | -19.4% |
| Cash & Short-Term Equivalents | $93.0M | $58.5M | — |
| Total Debt (Short + Long Term) | $220.7M | $240.8M | $613.5M |
| Total Stockholders' Equity | $114.8M | $59.1M | $1.26B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR TVTX.